Robert Mashal is responsible for developing the overall strategy for the oncology and I&I (immunology and inflammation) franchises in collaboration with the leadership in research, development, and the GBU.
- CEO, NKT Therapeutics
- CEO, Alinea Pharmaceuticals
- Partner, Boston Millennia Partners (BOD member Glycofi, Cardiomems, Novalar, Sapphire, CoApt Systems)
- Program Executive, Vertex Pharmaceuticals
- Consultant, McKinsey & Co.
- Johns Hopkins University
- Johns Hopkins University, Economics/Natural Sciences